Stoke Therapeutics (NASDAQ:STOK) Now Covered by Analysts at Guggenheim

Guggenheim initiated coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a report issued on Thursday morning, MarketBeat reports. The brokerage issued a buy rating and a $60.00 price objective on the stock.

STOK has been the subject of a number of other reports. UBS Group set a $50.00 target price on shares of Stoke Therapeutics in a research note on Monday, December 15th. Wedbush boosted their price objective on Stoke Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a research report on Monday, January 12th. Canaccord Genuity Group raised their target price on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Needham & Company LLC lifted their target price on Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, October 10th. Finally, BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.18.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $32.40 on Thursday. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 48.36 and a beta of 1.10. Stoke Therapeutics has a one year low of $5.35 and a one year high of $38.69. The stock has a 50-day simple moving average of $31.46 and a 200 day simple moving average of $26.20.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The business had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. On average, equities research analysts forecast that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 13,430 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $32.27, for a total value of $433,386.10. Following the transaction, the director owned 49,124 shares of the company’s stock, valued at approximately $1,585,231.48. This represents a 21.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Barry Ticho sold 3,662 shares of Stoke Therapeutics stock in a transaction on Friday, December 5th. The stock was sold at an average price of $31.34, for a total value of $114,767.08. Following the completion of the transaction, the insider owned 19,798 shares in the company, valued at $620,469.32. The trade was a 15.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 98,774 shares of company stock worth $2,918,365 in the last ninety days. 9.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Stoke Therapeutics by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after acquiring an additional 217,616 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Stoke Therapeutics by 7.9% in the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after purchasing an additional 168,771 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after purchasing an additional 293,072 shares in the last quarter. Polar Capital Holdings Plc boosted its position in shares of Stoke Therapeutics by 49.8% in the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after buying an additional 439,824 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Stoke Therapeutics by 36.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,227,723 shares of the company’s stock valued at $38,968,000 after buying an additional 327,451 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.